UC Glossary and Reference Citations

Glossary

ADC, antibody drug conjugate

ADCC, antibody-dependent cell-mediated cytotoxicity

AEs, adverse events

APNs, advanced practice nurses

BCOPs, board certified oncology pharmacists

BSA, body surface area

BSC, best supportive care

Bx, biopsy

Chemo, chemotherapy

CNSs, clinical nurse specialists

CPS, combined positive score

CR, complete response

CS, corticosteroid(s)

CT, computed tomography

DD-MVAC, dose dense-Methotrexate, Vinblastine, Doxorubicin, Cisplatin

DOC, docetaxel

Dx, diagnose(d)

Dz, disease

ECOG PS, Eastern Cooperative Oncology Group Performance Status

ESMO, European Society for Medical Oncology

FcR, crystallizable fragment region

FGFR, fibroblast growth factor receptor

GemCis, gemcitabine + cisplatin

Hx, history

ICs, immune cells

ICI(s), immune checkpoint inhibitor(s)

irAE(s), immune-related adverse event(s)

IV, intravenous

mDOR, median duration of response

mets, metastases

MHC, major histocompatibility complex

MOA, mechanism of action

mos, months

mOS, median overall survival

mPFS, median progression-free survival

mUC, metastatic urothelial carcinoma

muts/Mb, mutations per megabase

NCCN, National Comprehensive Cancer Network

NK cells, natural killer cells

NPs, nurse practitioners

OCNs, oncology clinical nurses

ORR, objective response rate

OS, overall survival

PAs, physician assistants

PAX, paclitaxel

PD-1, programmed death cell protein 1

PD-L1, programmed death cell protein ligand 1

PET, positron emission tomography

PN, peripheral neuropathy

pt(s), patient(s)

QOL, quality of life

RCT, randomized controlled trial

RECIST, Response Evaluation Criteria in Solid Tumors

SOC, standard of care

TCs, tumor cells

TCS, topical corticosteroid(s)

TMB, tumor mutational burden

TUR, transurethral resection

Tx, treatment/treated/therapy

UC, urothelial carcinoma

UTIs, urinary tract infections

VFL, vinflunine

w/, w/o, with, without

wks, weeks

WHO, World Health Organization

UC Glossary and Reference Citations

References

Bellmunt J, Orsola A, Leow JJ, DeSantis M, Horwich A. Bladder Cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014;25(Suppl 3):iii40-iii48.

Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *N Engl J Med*. 2017;376:1015-1026.

Collins JM, Gulley JL. Product review: avelumab, an anti-PD-L1 antibody. *Hum Vaccin Immunother*. 2019;15:891-908.

Ding X, Chen Q, Yang Z, et al. Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. *Cancer Manag Res*. 2019;11:4171-4184.

Eckstein M, Cimadamore A, Hartmann A, et al. PD-L1 assessment in urothelial carcinoma: a practical approach. *Ann Transl Med*. 2019;7:690.

ESMO Guidelines Committee. eUpdate — Bladder Cancer Treatment Recommendations. Published 16 December 2019. https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer/eupdate-bladder-cancer-treatment-recommendations3. Accessed August 13, 2020.

Food and Drug Administration (FDA). FDA approves avelumab for urothelial carcinoma maintenance treatment. FDA press release. June 30, 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment. Accessed August 13, 2020.

Food and Drug Administration (FDA). FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. FDA press release. April 12, 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma. Accessed August 13, 2020.

Food and Drug Administration (FDA). FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer. FDA press release. December 18, 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-metastatic-urothelial-cancer. Accessed August 13, 2020.

Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of immune-related adverse effects of immune checkpoint inhibitors: a review. *JAMA Oncol*. 2016;2:1346-1353.

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours. *Eur Urol*. 2016;70:106-119.

Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial cancer. *N Engl J Med*. 2019;381:338-348.

Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. *Ann Oncol*. 2015;26:2375-2391.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 6.2020 — July 16, 2020. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed August 13, 2020.

Petrylak DP. Immunotherapy: the wave of the future in bladder cancer? *Clin Genitourin Cancer*. 2017;15:S3-S17.

Petrylak DP, Balar AV, O'Donnell PH, et al. EV-201: results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. *J Clin Oncol*. 2019;37(18 Suppl):4505.

Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. *N Engl J Med*. 2020; 383:1218-1230.

Powles T, Walker J, Williams JA, Bellmunt J. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. *Cancer Treat Rev*. 2020;82;101925.

Puzanov I, Diab A, Abdalla K. Managing toxicities associated with checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer Toxicity Management Working Group. *J Immunotherapy Cancer*. 2017;5:95.

Rao A, Patel MR. A review of avelumab in locally advanced and metastatic bladder cancer. *Ther Adv Urol*. 2019;11:1-7.

Rosenberg JE, O'Donnell PH, Belar AF, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. *J Clin Oncol*. 2019;37:2592-2600.

Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors—an overview. *Rheumatology*. 2019;58(Suppl 7):vii7-vii916.

Wang G, McKenney JK. Urinary bladder pathology: World Health Organization classification and American Joint Committee on Cancer Staging update. *Arch Pathol Lab Med*. 2019;143:571-577.

Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol*. 2012;30:2691-2697.